Tryptase reference values in a Swedish middle-aged general population and association with diabetes mellitus

Joana Vitte, Anders Sjölander, Niclas Rydell, Magnus Molin, Gunnar Pejler, Jenny Hallgren, Robert Movérare, Christer Janson, Andrei Malinovschi

To cite this version:
Joana Vitte, Anders Sjölander, Niclas Rydell, Magnus Molin, Gunnar Pejler, et al.. Tryptase reference values in a Swedish middle-aged general population and association with diabetes mellitus. Clinical and Experimental Allergy, 2022, 52 (11), pp.1330-1333. 10.1111/cea.14195. hal-03823975

HAL Id: hal-03823975
https://amu.hal.science/hal-03823975
Submitted on 27 Sep 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License
Tryptase reference values in a Swedish middle-aged general population and association with diabetes mellitus

To the Editor,

Mast cell (MC) tryptase is a tetrameric protease stored in the secretory granules in its active form and released upon strong activation signals which lead to degranulation. However, inactive monomeric pro-tryptases seem to be continuously secreted, and contribute to baseline serum tryptase.\(^1\) The increasing use of serum tryptase (hereafter “tryptase”) as a biomarker parallels the progress in our understanding of MC pathophysiology. Established as a biomarker of anaphylaxis and mastocytosis, tryptase is now accepted as a predictor of the risk and severity of allergic reactions.\(^2\) Its value has also been suggested in conditions frequently affecting middle-aged subjects, such as atherosclerosis, metabolic syndrome and kidney disease.\(^1,2\) Age-adjusted tryptase reference values are scarcely available, despite reports on the age-related increase in tryptase levels, especially after 50 years.\(^3,4\) Here, we report on tryptase determinants in a general population cohort of middle-aged Swedes and establish reference tryptase levels in subjects free of such conditions.

The multicentric Swedish CARDiopulmonary biomage Study (SCAPIS) consisted of randomly selected men and women aged 50–64. Participants gave their written and informed consent prior to filling in a comprehensive questionnaire (self-reported physician-diagnosed diseases) and undergoing extensive physical examination, lung function tests and blood sampling.\(^5\) Tryptase was an add-on measurement in the Uppsala cohort, comprising 5036 subjects recruited between October 2015 and June 2018. Approval was obtained from the Regional Ethical Review Boards of Umeå (SCAPIS, 2010–228-31M) and Uppsala (total tryptase determination for the present study, 2018–272).

Tryptase was measured by the ImmunoCAP total tryptase assay (Thermo Fisher Scientific) in 4915 subjects (121 missing samples). Univariate analyses were performed with regard to known determinants of tryptase, mainly age, gender, body mass index (BMI), renal function\(^1,3\) and different diseases (Table 1). In our cohort, male gender, older age, obesity (defined as BMI ≥ 30 kg/m\(^2\)), current smoking, hypertension, elevated creatinine (defined as >100 μM in men and >90 μM in women), diabetes mellitus (hereafter “diabetes”) and chronic sinusitis related to increased tryptase levels. Other diseases or variables measured in the SCAPIS cohort were not related to variations in tryptase levels (Table 1).

False Discovery Rate (FDR) correction was done by the Benjamini-Hochberg method (Table 1). The findings for gender, hypertension and chronic sinusitis were not consistent after FDR adjustment. Next, a multiple linear regression model applied to variables with FDR-adjusted \(p<.05\), that is, age, obesity, current smoking, creatinine and diabetes, showed that these were independently related with tryptase levels (not shown). Therefore, reference tryptase levels (median, 5th and 95th percentiles) were determined from 3057 SCAPIS participants free of tryptase-modifying conditions demonstrated in this cohort, that is, diabetes, obesity, elevated creatinine and current smoking. Using this approach, the median reference levels between 50 and 59 years were 5.41 μg/L for women and 5.64 μg/L for men, while between 60 and 65 years the corresponding levels were 5.67 μg/L for women and 5.84 μg/L for men (Table 2). These levels were higher than the 3.4 μg/L tryptase geometric mean provided by the manufacturer, underscoring the need for population-based reference values. The 95th percentile in each reference group was between 10.40 and 12.79 μg/L, also higher than most of the recent, updated values reported by the manufacturer and the literature: 8.20, 9.56 and 11.00 μg/L\(^3,6\) (manufacturer’s expected values https://dfu.phadia.com/Data/Pdf/5d23154289c2320348332cfdf.pdf, https://dfu.phadia.com/Data/Pdf/5db0691d89c23208b036f94.pdf). It is currently considered that more than 90% of people with tryptase levels greater than 11.4 μg/L carry excess \(\alpha\)-tryptase alleles, a condition known as hereditary \(\alpha\)-tryptasemia,\(^1\) however, it is unknown whether age-related variations are present in people with this condition. Moreover, an estimated 1% of people with tryptase levels greater than 11.4 μg/L are affected by a myeloid neoplasm, which may be indolent and/or undiagnosed.\(^1\)

Our findings confirm and complete a recent study on age-related tryptase variation in a Dutch cohort, which reported upper reference limits in the oldest (70 years and older) age group higher than the currently used 11.4 μg/L cut-off.\(^8\) In addition, clinical data available for SCAPIS participants allowed us to assess tryptase determinants.

To our best knowledge, this is the first report on diabetes as an independent determinant of tryptase levels. Despite accumulating experimental data of MC involvement in the pathophysiology of diabetes, tryptase levels in patients with this condition have been...
seldom addressed and significant variations were not evidenced.\textsuperscript{7} Our finding of a slight but significant increase in tryptase levels in middle-aged patients affected by diabetes, independently from cardiovascular, metabolic or renal conditions, is consistent with previous evidence of MC involvement in insulin resistance development in mice and the report of a positive association between tryptase and fasting insulin levels\textsuperscript{2,8}. An association between pre-diabetes or diabetes with MC tryptase levels could not be demonstrated in previous studies from a Chinese team, possibly because of different trial design and laboratory methods, notably inclusion criteria focusing on diabetes epidemiology, age range including middle-aged and elderly subjects aged 55–75, and tryptase determination with an in-house ELISA.\textsuperscript{7} In the SCAPIS age range, type 2 diabetes is more prevalent than type 1 diabetes. We speculate that the design of the

### Key messages
- Serum tryptase was measured in a clinically characterized cohort of the Swedish general population aged 50–64.
- Cohort-derived reference values for this age group in the absence of tryptase-modifying conditions are provided.
- Diabetes mellitus is a novel, independent determinant for higher tryptase in the general population aged 50–64.

### Table 1

| Variable                                  | Yes        | No         | Univariate p-Value | FDR-adjusted p-Value |
|-------------------------------------------|------------|------------|--------------------|----------------------|
| Female gender                             | 5.77 (5.69; 5.86) (2518) | 5.91 (5.81; 6.01) (2397) | .045               | .14                  |
| Age ≥ 60 years                             | 6.05 (5.94; 6.16) (3179) | 5.72 (5.64; 5.81) (1736) | <.00001            | .0001                |
| Obesity (BMI ≥ 30 kg/m\(^2\))             | 6.07 (5.92; 6.22) (1044) | 5.78 (5.70; 5.85) (3871) | .0004              | .0020                |
| Current smoking                           | 6.28 (6.02; 6.55) (407) | 5.80 (5.73; 5.88) (4182) | .0002              | .0017                |
| Atopy                                     | 5.76 (5.63; 5.88) (1261) | 5.86 (5.79; 5.94) (3643) | .16                | .31                  |
| Asthma                                    | 5.66 (5.41; 5.91) (310) | 5.85 (5.78; 5.92) (4306) | .16                | .31                  |
| Allergic rhinitis                         | 5.84 (5.69; 5.99) (1034) | 5.81 (5.74; 5.89) (3487) | .75                | .84                  |
| Chronic sinusitis                         | 6.40 (5.92; 6.93) (103) | 5.81 (5.74; 5.88) (4470) | .0164              | .07                  |
| Heart infarction                          | 5.75 (5.09; 6.49) (61) | 5.84 (5.77; 5.91) (4549) | .77                | .84                  |
| Angina pectoris                           | 6.50 (5.40; 7.83) (28) | 5.83 (5.76; 5.90) (4582) | .16                | .31                  |
| Atrial fibrillation                       | 5.82 (5.32; 6.38) (83) | 5.84 (5.77; 5.91) (4527) | .96                | .96                  |
| Heart failure                             | 6.53 (5.32; 8.01) (19) | 5.83 (5.76; 5.90) (4591) | .23                | .41                  |
| Valvular disease                          | 6.33 (5.65; 7.10) (30) | 5.83 (5.76; 5.90) (4580) | .75                | .84                  |
| Bypass/Percutaneous coronary intervention | 5.67 (4.66; 6.89) (31) | 5.84 (5.77; 5.91) (4579) | .69                | .82                  |
| Arterial disease                          | 5.18 (3.35; 8.03) (9) | 5.84 (5.77; 5.91) (4601) | .38                | .53                  |
| Intervention of aorta aneurysm             | 7.25 (2.98; 17.69) (4) | 5.83 (5.77; 5.90) (4590) | .28                | .44                  |
| Stroke                                    | 5.97 (5.38; 6.62) (51) | 5.83 (5.77; 5.90) (4599) | .69                | .82                  |
| High blood pressure                       | 5.98 (5.83; 6.13) (1018) | 5.80 (5.72; 5.87) (3592) | .035               | .13                  |
| High cholesterol                          | 5.86 (5.66; 6.06) (568) | 5.83 (5.76; 5.91) (4042) | .84                | .88                  |
| Diabetes mellitus                         | 6.65 (6.27; 7.06) (208) | 5.80 (5.73; 5.87) (4402) | <.00001            | .0001                |
| High creatinine (male > 100μM, female > 90μM) | 6.44 (6.05; 8.66) (364) | 5.81 (5.74; 5.88) (4433) | .0003              | .0019                |
| Chronic obstructive pulmonary disease      | 6.18 (5.36; 7.13) (41) | 5.83 (5.76; 5.90) (4569) | .37                | .53                  |
| Respiratory disease other than asthma or COPD | 6.46 (5.88; 7.10) (59) | 5.83 (5.76; 5.90) (4551) | .053               | .15                  |
| FEV\(^1\) < 80% predicted                 | 5.95 (5.49; 6.45) (122) | 5.83 (5.77; 5.90) (4677) | .60                | .79                  |
| FEV\(^1\)/FVC < 0.70                      | 6.01 (5.75; 6.27) (364) | 5.82 (5.76; 5.89) (4433) | .16                | .31                  |

Note: Serum tryptase levels (μg/L) are presented as geometric mean and 95% confidence interval. Sample size is indicated. False-discovery rate (FDR) correction was done by Benjamini-Hochberg method. p-Values <.05 are denoted in bold font.

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV\(^1\), forced expiratory volume in 1 second; FEV\(^1\)/FVC ratio, Tiffeneau-Pinelli index; FVC, forced vital capacity; μM, micromoles per litre.
TABLE 2 Reference values for serum tryptase according to age and gender

|                  | 50–59 years | 60–65 years |
|------------------|-------------|-------------|
| All subjects     |             |             |
| (n = 3057)       | 5.51 (3.14; 10.40) | 5.74 (3.31; 11.82) |
| (n = 1984)       |             | (n = 1073)  |
| Male subjects    |             |             |
| (n = 1398)       | 5.64 (3.13; 10.49) | 5.84 (3.25; 11.70) |
| (n = 925)        |             | (n = 473)   |
| Female subjects  |             |             |
| (n = 1659)       | 5.41 (3.16; 10.40) | 5.67 (3.40; 12.79) |
| (n = 1059)       |             | (n = 600)   |

Note: Serum tryptase levels are expressed in micrograms per litre and presented as median (5th; 95th percentiles). n, sample size.

SCAPIS study, addressing a homogeneous population within a narrow age range matching type 2 diabetes onset, favoured its identification as a new determinant.

Another new finding is the association of higher tryptase levels and chronic sinusitis. MC involvement was described in endotype T2 of chronic sinusitis. However, our finding was weaker and not consistent after adjustment for multiple testing (p value .07). Asthma, which is frequently associated with a T2 response, and atopy alike did not affect tryptase levels in our cohort, in line with reports from other cohort studies.

As expected from previous literature reports, tryptase levels were higher in smokers, in obese participants and in people with elevated creatinine levels. Our results on the association of diabetes and higher tryptase levels were however consistent after adjusting for current smoking, elevated creatinine and obesity.

The strengths of our study comprise the assessment of a large sample of general population with in-depth clinical characterization, focusing on a middle-age interval (50–64 years), performed within a short time frame (32 months between 2015 and 2018), and relying on the same, most recent tryptase assay version. The main weakness is the lack of screening for primary MC-related conditions, above all hereditary α-tryptasemia, which can be diagnosed using a digital droplet PCR method, as published in 2016 when the SCAPIS study had already been designed and the sampling was ongoing. The proposed reference values underscore the importance of performing paired tryptase sampling in systemic hypersensitivity reactions including anaphylaxis in middle-aged populations, given the prevalence of high baseline tryptase levels.

These reference values should prove useful in the context of the expanding use of tryptase as a cardiovascular and metabolic biomarker, of tryptase genotyping for hereditary α-tryptasemia, and of better knowledge of tryptase increase in indolent myeloid neoplasms. Finally, the proposed reference values underscore the importance of performing paired tryptase sampling in systemic hypersensitivity reactions including anaphylaxis in middle-aged populations, given the prevalence of high baseline tryptase levels.

AUTHOR CONTRIBUTIONS

JV, AS, NR, MM, GP, JH, RM, CJ and AM participated in the study design, interpretation of the data, drafting the manuscript and approved the final version of the manuscript. JV, CJ and AM prepared the first draft of the manuscript. AM performed the statistical analysis. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

FUNDING INFORMATION

The main funding body of the Swedish CARDioPulmonary biomage Study is the Swedish Heart and Lung Foundation. The study is also funded by the Knut and Alice Wallenberg Foundation, the Swedish Research Council and VINNOVA (Sweden’s Innovation Agency), the University of Gothenburg and Sahlgrenska University Hospital, Karolinska Institutet and Stockholm County council, Linköping University and University Hospital, Lund University and Skåne University Hospital, Umeå University and University Hospital, Uppsala University and University Hospital. There was also individual research support from the Swedish state under the ALF agreement between the Swedish government and the county councils. Thermo Fisher Scientific has performed the tryptase testing as part of a research collaboration agreement with Uppsala University.

FUNDING INFORMATION

Akademiska Sjukhuset; ALF; Göteborgs Universitet; Karolinska Institutet; Knut och Alice Wallenbergs Stiftelse; Linköping University Hospital; Linköpings Universitet; Lunds Universitet; Sahlgrenska Universitetssjukhuset; Skånes Universitetssjukhus; Stockholms Läns Landsting; Svenska Forskningsrådet Formas; Swedish Heart and Lung Foundation, Grant/Award Number: 20170673; Thermo Fisher Scientific; Umeå Universitet; Umeå University Hospital; Uppsala Universitet; VINNOVA

CONFLICT OF INTEREST

AS, NR, RM and MM are employed by Thermo Fisher Scientific. JV reports speaker and consultancy fees in the past 5 years from Astra Zeneca, Meda Pharma (Mylan), Novartis, Sanofi, Thermo Fisher Scientific, outside the submitted work. The other authors declare no competing interests in relation to this study.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available. All subjects.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available.
available due to privacy or ethical restrictions. More information can be found at http://scapis.org/